UPCC 26423 Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCR and 4-1BB Signaling Domains in Combination with CD33KO-HSPC in Subjects with Refractory or Relapsed Acute Myeloid Leukemia
Enrolling By Invitation
99 years and younger
All
Phase
N/A
32 participants needed
1 Location
Brief description of study
Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 854325
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
